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Background: The molecular basis to overcome therapeutic resistance to treat glioblastoma remains unclear. The
anti-apoptotic b cell lymphoma 2 (BCL2) gene is associated with treatment resistance, and is transactivated by the
paired box transcription factor 8 (PAX8). In earlier studies, we demonstrated that increased PAX8 expression in
glioma cell lines was associated with the expression of telomerase. In this current study, we more extensively
explored a role for PAX8 in gliomagenesis.
Methods: PAX8 expression was measured in 156 gliomas including telomerase-negative tumours, those with the
alternative lengthening of telomeres (ALT) mechanism or with a non-defined telomere maintenance mechanism
(NDTMM), using immunohistochemistry and quantitative PCR. We also tested the affect of PAX8 knockdown using
siRNA in cell lines on cell survival and BCL2 expression.
Results: Seventy-two percent of glioblastomas were PAX8-positive (80% telomerase, 73% NDTMM, and 44% ALT).
The majority of the low-grade gliomas and normal brain cells were PAX8-negative. The suppression of PAX8 was
associated with a reduction in both cell growth and BCL2, suggesting that a reduction in PAX8 expression would
sensitise tumours to cell death.
Conclusions: PAX8 is increased in the majority of glioblastomas and promoted cell survival. Because PAX8 is absent
in normal brain tissue, it may be a promising therapeutic target pathway for treating aggressive gliomas.
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Glioblastomas are the most common histological sub-
type among all the malignant brain tumours [1,2]. With
the distinct molecular subtypes of glioblastoma recently
characterised, the hope of new glioblastoma therapeutics
is imminent [3-5]. Paired box-containing (PAX) tran-
scription factors are largely expressed during develop-
ment and at low levels in adult tissue [6]. Aberrant PAX
gene expression is present in multiple cancer types, in-
cluding cancers of the lymphoid tissue, thyroid, kidney,
breast, and endometrium [7-10]. Paired box-containing
proteins also possess many tumour-promoting functions,
such as the promotion of cell survival and anti-apoptotic* Correspondence: tania.slatter@otago.ac.nz
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unless otherwise stated.properties, because a reduction in PAX gene expression
induces apoptosis in normal and tumour cells [11-15].
PAX8 is expressed at the midbrain-hindbrain junction
during brain development and is virtually absent in the
adult brain [16]. In earlier studies involving PAX8 and
glioblastomas, we found increased PAX8 expression in
tumours using a small panel of 14 telomerase-positive
tumours and cell lines [14,17]. The tumour-promoting
functions of PAX8 include the ability to transform cells
and to form tumours in mice [18], an increased telomer-
ase activity [17], and the promotion of cell cycle pro-
gression [19]. The genes upregulated by PAX8 include b
cell lymphoma 2 (BCL2) and Wilms tumour 1 (WT1).
High-grade gliomas have a higher WT1 expression level
compared with low-grade gliomas [20], and BCL2 is
associated with the higher tumour grades, poorer pa-
tient survival, and the conferring of treatment resistancetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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family members [21-25].
The prevalence of increased PAX8 expression has not
been extensively explored in glioma, especially with
regard to the effect of increased PAX8 expression in
telomerase-negative gliomas. Here, we surveyed the
PAX8 expression in a range of brain tumours, including
different grades of gliomas and varieties of telomere
maintenance mechanisms.Methods
Tumour samples
Brain tumours were procured during surgery from patients
admitted to New Zealand hospitals. The Multi-region Eth-
ics Committee, New Zealand, approved this study, and all
patients provided written informed consent. Each hospital
made the original histological diagnoses, which were subse-
quently reviewed by consultant neuropathologists at the
referral centres, and confirmed by the study consultant
neuropathologist who was blind to the original diagnoses.
The glioblastomas used in this already had the telomere
maintenance mechanism established as part of previous
studies or had the telomere maintenance mechanism
typed in the current study by methods outlined else-
where [26,27]. Briefly, ALT positive tumours had het-
erogeneous telomere lengths by terminal restriction
fragment (TRF) analysis and were positive for ALT asso-
ciated promyelocytic leukaemia nuclear bodies (APB),
but were negative for telomerase activity using the telo-
mere repeat amplification protocol (TRAP) assay. Tel-
omerase positive tumours were positive for telomerase
activity using the TRAP assay and did not have APBs or
heterogeneous telomere lengths by TRF analysis. NDTMM
tumours did not have heterogeneous telomeres by TRF
analysis and were negative for telomerase activity by TRAP
analysis.Immunohistochemistry (IHC)
Paraffin-embedded brain tissues were mounted on micro-
scope slides and were subjected to heat-mediated antigen
retrieval. Primary antibodies raised against PAX8 (MRQ-
50 and PAX8 [polyclonal] antibodies, Cell Marque, Rock-
lin, CA) and PAX5 (clone 24, Cell Marque, Rocklin, CA)
were used and detected using the EDL (Dako, Glostrup,
Denmark) and DAB methods. PAX5- or PAX8-positive
cells were detected with light microscopy, and the per-
centage of positive cells per 1000 tumours cells was
calculated (DM 2000 microscope, DFC 295 camera and
Application Suite software, version 3.5.0, Leica, Solms,
Germany). The slides were assessed by three authors (AS,
NH and TS) independently. A tumour was considered
positive for PAX8 or PAX5 when 10% or more of the
tumour nuclei were moderately or faintly stained by IHC.Quantitative PCR
Total RNA was extracted from glioma specimens using the
RNeasy Lipid Tissue Mini Kit (Qiagen, GmbH, Germany)
following the manufacturer’s instructions. For quantitative
PCR (QPCR), the first-strand cDNA from 50 ng RNA was
used. Relative quantification of the PAX8 transcripts and
the two housekeeping genes, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and hypoxanthine phosphoribo-
syltransferase 1 (HPRT1) by real time PCR was determined
utilising the SYBR-green detection protocol and the ABI
PRISM 7000 or 7300 Sequence Detection System (Life
Technologies, Carlsbad, CA). The primer sequences used
were as follows:
PAX8 forward primer: 5′-TTTGCTTGGCTCTTTCTA
CACCTC-3′
PAX8 reverse primer: 5′-GAATGTCTGTTTTAAGCT
CCCTGG-3′
GAPDH forward primer: 5′-TGCACCACCAACTGCT
TAGC-3′
GAPDH reverse primer: 5′-GGCATGGACTGTGGTC
ATGAG-3′
HPRT1 forward primer: 5′-TGACACTGGCAAAACAA
TGCA-3′
HPRT1 reverse primer: 5′-GGTCCTTTTCACCAGCA
AGCT-3′
The cycling conditions were 50°C for 2 min, 95°C for
10 min, and 40 cycles of 95°C for 15 s, 60°C for 1 min,
and then from 60°C to 95°C for 20 min. The relative ex-
pression levels were calculated using the ΔΔCt method
with the GAPDH and HPRT1 genes used as internal
controls. The tumours that expressed PAX8 at a level at
least 3 times higher than the HEK-293 cell (no or low
expression of PAX8) levels were considered positive
[28,29].
Construction and transfection of siRNAs
PAX8 siRNAs were designed following previously devel-
oped and described guidelines [30].




The other controls included:
Non-targeting 1 (NT1) to GFP: 5′-ACTACCAGCAGA
ACACCCC-3′
Scrambled sequence for PAX8-1 (sc8-1): 5′-AAGTTAG
AAAAAAACGAAAAG-3′
Scrambled sequence for PAX8-2 (sc8-2): 5′-AACACCG
GGAAACACCUTCCU-3′
Table 1 The frequency of PAX8- and PAX5-positive brain
tumours
Tumours type n PAX8-positive PAX5-positive
Glioblastoma: ALT 18 8 (44%)† 0
Glioblastoma: NDTMM 56 41 (73%)* 5 (9%)
Glioblastoma: telomerase 46 37 (80%)** 2 (5%)
Astrocytoma grade I 20 1 (5%) 0
Astrocytoma grade II 6 1 (17%) 0
Astrocytoma grade III 10 4 (40%) 0
Meningioma grade I 20 1 (5%) 0
Atypical Meningioma (Grade II) 6 0 -
Malignant Meningioma (Grade III) 4 4 (100%) 0
ALT, alternative lengthening of telomeres; NDTMM, non-defined telomere
maintenance mechanism. †, four positive tumours showed faint
immunostaining; *P < 0.05 and **P < 0.01 compared with ALT-positive
tumours; −, not tested.
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siRNA construction Kit (Life Technologies, Carlsbad, CA)
following the manufacturer’s instructions. The control
GAPDH siRNA template was provided with the kit. The
siRNA for p53 and the non-targeting 2 (NT2) control
siRNA were purchased from Qiagen (GmbH, Hilden,
Germany). Two additional siRNA for p53 sc29435 (siTP53
2 in this study) and sc44218 (siTP53 3 in this study) were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Three BCL2 siRNA were used (sc-61899) along with
the control siRNA (sc-37007, NT3), and were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Two
additional siRNA for BCL2 214532 (siBCL2 2 in this study)
and 214533 (siBCL2 3 in this study) purchased from Life
Technologies (Carlsbad, CA). All siRNAs were handled
and prepared according to manufacturers’ instructions.
The transfection experiments utilised A172 cells because
of their endogenous PAX8 expression, as previously de-
scribed [17]. Briefly, cells were plated at densities ran-
ging from 2 × 104 to 1 × 105 cells/well 24 hours prior to
transfection. The siRNAs were diluted with serum-free
medium to a final concentration of 10 nM and transi-
ently transfected into cells using Lipofectamine 2000
(Life Technologies, Carlsbad, CA) or Ambion siPORT
NeoFX (Life Technologies, Carlsbad, CA). The medium
was replaced after 4 hours, and the cells were harvested
24–96 hours after siRNA transfection. The viable cells
were counted using the trypan blue exclusion assay.
Apoptotic nuclei were detected in paraffin-embedded
cell clot sections using the Klenow FragEL DNA Frag-
mentation Kit (Merck, Darmstadt, Germany) and light
microscopy. The percentage of apoptotic cells per 500
cells was measured.
Western blot analysis
A172 protein lysates were prepared in the presence of
protease inhibitors, and 100 μg protein were separated
on NuPAGE 4-12% Bis-Tris Gels (Life Technologies,
Carlsbad, CA). Blots were probed with primary anti-
bodies raised against PAX8 (MRQ-50, Cell Marque),
Bcl-2 (Clone 124, Dako), p53 (1C12, Cell Signaling
Technology, Beverly, MA), WT1 (6FH2, Dako, Glostrup,
Denmark) and β-actin (AC-15, Abcam, UK) according
to the manufacturers’ instruction, or that optimised in
the current study (1:200 dilution for WT1). Alkaline
phosphatase conjugated antibodies were detected using
the Western Breeze Immunodetection kit (Life Tech-
nologies, Carlsbad, CA).
Statistical analysis
To analyse the PAX8-positive tumours, a comparison
between the experimental groups was made using the
Fisher’s exact test. For cell transfection experiments, the
data are expressed as the mean ± SD, and the statisticalsignificance was determined between the experimental
groups using the Student t test. P < 0.05 was considered
statistically significant and the GraphPad Prism software,
version 6.00 for Macintosh (GraphPad Software, San
Diego, CA) to perform all statistical tests.Results
Aggressive gliomas are PAX8-positive
The results from the immunohistochemical analyses are
presented in Table 1. PAX8-positive tumours were fre-
quently observed in 72% (86/120) of the glioblastoma
samples. The majority of the PAX8-positive glioblast-
omas possessed at least 60% PAX8-positive tumours
cells (Figure 1A). All tumours typed as negative for
PAX8 had no positive nuclear staining. PAX8-positive
glioblastomas were present in all the telomere mainten-
ance mechanism groups, but a higher prevalence was
observed in the telomerase-positive (80%) and NDTMM-
positive (73%) tumours compared with the ALT-positive
tumours (44%; P = 0.007 and P = 0.043, respectively). All
tumours had intense PAX8 immunostaining with the
exception of the ALT-positive tumours, of which 4/8
ALT-positive tumours showed faint PAX8 immuno-
staining. Glioblastomas typed as PAX8-negative had
no PAX8-positive tumour cells present (Figure 1C).
PAX8-positive tumours were also observed in other
aggressive tumours in the brain, including all malig-
nant meningiomas (n = 4) and 40% of grade 3 astrocy-
tomas (4/10).
A small number of the low-grade tumours were PAX8-
positive (6%, see Table 1). In the 52 cases of meningioma
and astrocytomas grades I and II, three PAX8-positive
cases were detected. PAX8-positive cases included one
recurrent grade I astrocytoma, one grade II astrocytoma,
and one meningioma (Figure 1B). All non-tumour brain
Figure 1 PAX8 immunostaining in gliomas. Representative examples of PAX8-positive and PAX8-negative immunostaining are illustrated
(A-D). Tissue sections were subjected to immunohistochemical stainings using an antibody raised against PAX8 (rabbit polyclonal, Cell Marque)
and counterstained with hematoxylin. PAX8-positive cells were detected by light microscopy. PAX8-positive cells were detected in glioblastoma
(A) and meningioma (B). (C) A PAX8-negative glioblastoma was observed at low (left) and high (right) magnification. (D) Normal brain tissue
adjacent to glioma cells was PAX8-negative except between the cerebellar molecular and nuclear layers. Examples of PAX8-positive cells are
highlighted with black arrows (tumours cells) and with red arrows (non-malignant cells).
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few PAX8-positive cells were identified in the cerebel-
lum between the molecular and the nuclear layer in the
two adult brain tumours containing cerebellum tissue
(Figure 1D).
All PAX8-positive tumours were verified as positive
using another PAX8 antibody raised against a region of
the C-terminus, which exhibits a lower homology with
PAX5. An IHC analysis of PAX5 expression in the brain
tumours cohort identified seven PAX5-positive tumours,
all glioblastomas (Table 1).
In summary, PAX8-positive cells were detected in
aggressive brain tumours. In low-grade gliomas, PAX8-
positive cases were infrequently observed.Quantitative PCR confirms the increase of PAX8
expression in glioblastomas
To confirm the prevalence of increased PAX8 expression
in primary glioblastomas, PAX8 expression was analyzed
using QPCR in 40 glioblastoma samples (30 positive and
10 negative by IHC), recurrent pilocytic astrocytomas,
PAX8-positive grade II astrocytomas, human fetal astro-
cytes derived from an 18-week gestated fetus (PAX8-
positive control), and HEK-293 cells (no or low PAX8
expression). Fetal-derived human astrocytes had 10-fold
more PAX8 expression than the embryonic kidney cell
line, HEK-293. The PAX8 expression was 10-fold higher
in 27/40 (68%) glioblastomas and the two low-grade
astrocytomas typed as PAX8-positive by IHC. Three
Hung et al. BMC Cancer 2014, 14:159 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/159glioblastomas showed a moderate PAX8 expression level
(from 5- to 10-fold higher), three had a low PAX8 ex-
pression level (from 3- to 5-fold higher). Seven tumours
showed less than a 2-fold increase in the PAX8 expres-
sion compared to HEK-293 cells and were typed as
PAX8-negative tumours. In summary, all tumours typed
as PAX8-positive by IHC were verified as PAX8-positive
by QPCR.Figure 2 Reduced PAX8 expression leads to a reduction in the glioma
silencing reduced the cell growth rate and induced apoptosis in three glio
and (C) U118MG, with mutant p53. Cells were transfected with a PAX8 siRN
transfected with non-targeting siRNAs (NT1, NT2, NT3, and scrambled s8-1
growth rate associated with the PAX8-knockdown was due to p53 function
with PAX8 (siPAX8 & p53). Live cells were counted using the trypan blue ex
percent viable and apoptotic cells 36 hours post-transfection are presented
with scPAX8).Glioma cell growth is inhibited by PAX8 siRNA gene
silencing
The silencing of PAX8 by siRNA was performed in three
glioma cell lines (A172, SF295, and U118MG) to examine
whether reduced PAX8 expression led to a reduction in gli-
oma cell growth (Figure 2). PAX8 was knocked-down with
three distinct siRNAs (PAX8-1, PAX8-2, and PAX8-3).
No significant differences in the PAX8 expression levelscell growth rate and increased glioma cell apoptosis. PAX8
ma cell lines: (A) A172, with wild-type p53; (B) SF295, with mutant p53;
A (siPAX8, PAX8-1). As controls, cells were mock-treated (Moc) or
(scPAX8)). To investigate whether the reduction in the glioma cell
, TP53 was also knocked down independently (sip53) or in combination
clusion assay at 24, 36, 48, 72, and 96 hours post-transfection. The
as bar graphs. *P < 0.05, **P < 0.01, and ***P < 0.001 (siPAX8 compared
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by western blotting (the result for PAX8-1 knockdown
compared to mock-transfected, or non-targeting siRNA
controls are shown in Figure 3A). The PAX8-knockdown
led to a reduction in cell number in all the glioma cell lines
(P < 0.01, PAX8 siRNA-knockdown compared with all con-
trols). PAX8 silencing by siRNA produced an increase in
apoptosis (Figure 2, far right panel) as measured by count-
ing the apoptotic cells 36 hours post-transfection (P < 0.05,
PAX8 siRNA compared with all controls). To ensure the
effect on cell growth was not p53 function-dependent, siR-
NAs to TP53 were also transfected into the A172, SF295,
and U118MG cell lines. An example of TP53-knockdown
in A172 cells by western blotting is presented in Figure 3A.
The TP53-knockdown was not associated with alterations
in cell numbers (Figure 2). The TP53 and PAX8 knock-
downs and cell survival studies in A172 cells were re-
peated using additional siRNAs (see Additional file 1).
PAX8 silencing leads to a reduction in tumour cell growth
and reduced BCL2 expression
Because PAX8 binds to the promoter region of BCL2 and
WT1 and enhances transcription [29,30], we investigatedFigure 3 Reduced PAX8 expression leads to decreased expression of BC
line by siRNA (PAX8-1) produced a reduction in the BCL2 expression levels. Cel
BCL2, p53, and β-actin (loading control) expression levels were measured by w
(Moc), non-targeting siRNAs (NT1, NT2, and NT3) and scrambled s8-1 siRNA (sc
with the PAX8-knockdown was not due to p53 function, p53 was also knocked
siRNA (siPAX8 & p53). (B) The PAX8-knockdown (siPAX8) in the A172 glioma ce
levels. (C) The BCL2-knockdown produced a similar reduction in the cell growt
were transfected with a BCL2 siRNA (siBCL2) or a PAX8 siRNA (PAX8-1, siPAX8).
non-targeting siRNAs (NT1 and NT3). The percentage of live cells was determin
(Insert) Western blotting shows the BCL2-knockdown with a BCL2 siRNA and nowhether the downregulation of PAX8 would decrease the
BCL2 and WT1 expression levels in glioma cells. PAX8
was knocked down using the PAX8-1 siRNA in A172 cells.
Western blots assessing the relative levels of BCL2 with
PAX8 knockdown revealed a reduction in the BCL2 ex-
pression (Figure 3A), whereas in the controls (mock trans-
fection, transfection with non-targeting siRNAs or the
scrambled siRNA [sc8-1]) no reduction in PAX8 or BCL2
expression was observed (Figure 3A). A similar result was
found for WT1, in which reduced WT1 was specific to ly-
sates with PAX8 knockdown (Figure 3B). These data sug-
gest that PAX8 silencing leads to downregulation of BCL2
and WT1 expression.
To investigate whether this reduction in BCL2 expres-
sion could explain the growth reduction associated with
the PAX8-knockdown, BCL2 was knocked down using a
BCL2 siRNA in A172 cells, and cell growth monitored
for 24–96 hours after transfection. BCL2 silencing re-
sulted in a reduction in glioma cell growth similar to the
reduction observed with PAX8 silencing (Figure 3C) at
48–96 hours post-transfection (P < 0.01, BCL2 siRNA
compared with controls). This observation provides fur-
ther evidence that the effect of PAX8 on BCL2 expressionL2 and WT1. (A) The PAX8-knockdown (siPAX8) in the A172 glioma cell
ls lysates were prepared 36 hours after siRNA transfection, and the PAX8,
estern blot. For controls, A172 cells were transfected with mock-treated
PAX8). To ensure the reduction in the glioma cell growth rate associated
down in A172 cells (sip53) independently or in combination with a PAX8
ll line by siRNA (PAX8-1) produced a reduction in the WT1 expression
h rate compared to PAX8-knockdown in the A172 glioma cell line. Cells
For controls, A172 cells were mock-transfected (Moc) or transfected with
ed by the trypan blue exclusion assay every 24 hours post-transfection.
BCL2-knockdown in controls; the loading control is β-actin.
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growth [31,32]. The BCL2 knockdown and cell survival
studies in A172 cells was repeated using additional siR-
NAs (see Additional file 1).
Discussion
The current study represents the first extensive analysis
of the PAX8 expression levels in gliomas. Our data
showed that PAX8 is increased in most high-grade gli-
omas and is a pro-survival factor for glioma cells. In
another study with a large tumour panel, PAX8-positive
tumours were frequently detected in renal cell carcin-
omas (90%), thyroid cancers (90%), endometrial cancers
(84%), cervical adenocarcinomas (83%), and ovarian
cancers (79%) [33]. Our data include glioblastoma and
malignant meningioma amongst the cancers with a high
incidence of PAX8-positive tumours. PAX8 transacti-
vates the promoters of the telomerase catalytic subunit
(hTERT) and the telomerase RNA component (hTR) to
increase telomerase activity [17], and as might be pre-
dicted, the majority of the telomerase-positive tumours
were also PAX8-positive. Therefore, in telomerase-
positive glioblastomas, the PAX8 expression may play
an important part in the immortalisation process by
regulating telomerase activity. But PAX8 expression was
not restricted to telomerase-positive glioblastomas. The
frequency of PAX8-positive tumours was similar be-
tween the telomerase- and NDTMM-positive tumours
and was lower in the ALT-positive glioblastomas (44%
of tumours, of which only half showed strong PAX8
immunostaining).
In cancer, the over-expression of the PAX genes is often
attributed to chromosomal rearrangements that result in
fusion proteins [7,10,34,35]. In thyroid adenocarcinomas
the PAX8/PPAR-γ (peroxisome proliferator-activator re-
ceptor gamma 1) fusion protein confers many oncogenic
properties, including increased proliferation, decreased
apoptosis and the inhibition of wild-type PPAR-γ [7,36-38].
The cause for the increased PAX8 expression in glioblast-
omas is unknown. In gliomas, the chromosome 2q13
locus, where the PAX8 gene is located, is not a glioma sus-
ceptibility locus (OMIM #137800), but other mechanisms
for the increased PAX expression in cancer have been
described. Hypomethylation, for example, produces an
increase in PAX2 expression in endometrioid carcinoma
[9]. In adult tissues, the PAX genes are proposed to be
important for maintaining stem cells; therefore, the
increased PAX8 expression in glioblastomas may be in-
dicative of an early cell lineage [39]. Additionally, co-
activators of PAX8 are increased in gliomas. Increased
TAZ (transcriptional co-activator with PDZ-binding
motif ) is observed in the mesenchymal subtype of glio-
blastoma [40,41]. Furthermore, TAZ is reduced in pro-
neural glioblastomas, which are usually ALT-positivetumours and those with reduced PAX8 positivity in the
current study [41].
In low-grade gliomas, PAX8 was not detected in the
majority of tumours. A reduction of the PAX8 expres-
sion levels in low-grade tumours is consistent with the
association of PAX8 expression with more aggressive tu-
mours. Our results are also consistent with another study
in which the transcriptional target of PAX8, WT1, was de-
creased in low-grade compared with high-grade gliomas
[20]. A larger cohort of the low-grade PAX8-positive tu-
mours might show an association with poorer outcomes
because in our cohort, the single PAX8-positive grade I
astrocytoma was a recurrent tumour.
In non-malignant cells, PAX8 expression was detected
in a minimal number of cerebellar cells. Otherwise, all
other non-malignant cells examined were PAX8-negative.
The virtual absence of PAX8 in the adult brain is consist-
ent with studies in mice in which the adult murine brain
expressed PAX8 at levels no higher than the background
signal [16]. PAX8 expression in the adult human brain has
not been previously studied, and our results suggest that
the residual PAX8 expression does occur in a small mi-
nority of cells. The predominance of high-grade gliomas
expressing high levels of PAX8 and the virtual absence of
PAX8 expression in normal brain makes PAX8 signalling
an appealing therapeutic target pathway.
We found that PAX8 acted as a pro-survival factor for
glioblastomas. The silencing PAX8 in several glioma cell
lines caused a marked reduction in cell number, which is
partly explained by an increase in apoptosis. Reduced PAX8
expression produced a reduction in the BCL2 expression
levels, and BCL2 inhibition by siRNA-knockdown reduced
the glioma cell growth rate. These findings are consistent
with previous reports that demonstrate PAX expression en-
hances cell growth and survival [15,42], and upregulated
BCL2 is found in gliomagenesis [21,31]. In other studies
BCL2 silencing induced cell death in vitro [43,44], led to an
arrest of cell cycle progression [19], and was associated with
the downregulation of multiple developmental genes [45].
Conclusions
Increased PAX8 expression was frequently detected in
high-grade gliomas. This finding combined with the re-
duction in glioma cell growth caused by a reduction in
Bcl-2 expression after PAX8-knockdown and the small
amount of PAX8 expression in normal brain tissue sug-
gests that PAX8 would be a suitable target pathway for
glioma therapy.
Additional file
Additional file 1: Validation of cell survival results using additional
siRNAs to PAX8, TP53, and BCL2. (A) Additional siRNAs (PAX8 2–3,
TP53 2–3, and BCL2 2–3) in the A172 glioma cell line by siRNA produced
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prepared 36 hours after siRNA transfection, and the PAX8, BCL2, p53, and
β-actin (loading control) expression levels were measured by western
blot. For controls, A172 cells were transfected with mock-treated (Moc),
non-targeting siRNAs (NT1, and NT3). (B) To ensure the additional siRNAs
had the same affect on cell survival the A172 cell growth rate was
measured for PAX8-knockdown with siRNA 2 and 3 (top panel), TP53
siRNA 2 and 3 (top panel), and BCL2 siRNA 2 and 3 (bottom panel). The
results were similar to that found with the original si RNAs (PAX8-1,
TP53-1, and BCL2-1 Figures 2 and 3). For controls, A172 cells were
mock-transfected (Moc) or transfected with non-targeting siRNAs (NT1 for
PAX8 and TP53 knockdowns and NT3 for BCL2 knockdowns). The
percentage of live cells was determined by the trypan blue exclusion
assay every 24 hours post-transfection.
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